Diabetes mellitus type 2 (T2DM) is a globally prevalent metabolic disorder associated with macrovascular and microvascular complications. The number of patients diagnosed with T2DM has exceeded 460 million worldwide and continues to rise. Insulin resistance is a primary pathogenic factor contributing to various systemic complications. Glycated hemoglobin (HbA1c) is a critical biomarker for monitoring glucose control in T2DM patients.
This study aimed to compare the mean platelet volume (MPV) between different groups of T2DM patients to assess the impact of disease progression and glycemic control. A total of 152 patients were categorized based on disease duration and glycemic control. The results showed that patients diagnosed for less than one year had a mean MPV of 9.8±1.0 fl, while those diagnosed for more than five years had a mean MPV of 9.0±0.95 fl. Comparative analysis with international studies indicated that MPV is significantly higher in diabetic patients than in non-diabetic individuals. Furthermore, patients with poor glycemic control exhibited a decrease in platelet count, aligning with findings in metabolic disease research.
The study findings suggest that both disease duration and glycemic control status influence platelet volume and count variations. Monitoring MPV can serve as an early indicator of diabetes-related complications. This research underscores the importance of continuous platelet parameter assessment in diabetic patients to predict and manage potential vascular complications effectively.